Edges in Network
| Network | GSE5851_top500tf - GSE5851 - SiGN-BN HC+Bootstrap |
| Network Description | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| Node | SALL1 |
| Upstream (Parents) |
|---|
| (<<) VTN → SALL1 |
| (<<) NR1H4 → SALL1 |
| Downstream (Children) |
|---|
| SALL1 → HLF (>>) |
| SALL1 → ZIC1 (>>) |
| SALL1 → NR1I3 (>>) |
| SALL1 → HOXB13 (>>) |
| SALL1 → CUX2 (>>) |
| SALL1 → ONECUT1 (>>) |
| SALL1 → ESR1 (>>) |
| SALL1 → SOX5 (>>) |
| SALL1 → HMGA2 (>>) |
| SALL1 → HOXA1 (>>) |
| SALL1 → EN2 (>>) |
| SALL1 → GLI2 (>>) |
| SALL1 → GATA4 (>>) |
| SALL1 → ATF5 (>>) |
| SALL1 → LHX2 (>>) |
| SALL1 → HHEX (>>) |
| SALL1 → ETV4 (>>) |
| SALL1 → SIX2 (>>) |
| SALL1 → AR (>>) |
| SALL1 → HR (>>) |
| SALL1 → NR5A2 (>>) |
| SALL1 → MYBL2 (>>) |
| SALL1 → MZF1 (>>) |
| SALL1 → PRRX1 (>>) |
| SALL1 → CEBPD (>>) |
| SALL1 → TCF21 (>>) |
| SALL1 → NRL (>>) |
| SALL1 → NR4A1 (>>) |
| SALL1 → FOSL2 (>>) |
| SALL1 → EMX1 (>>) |
| SALL1 → MYCN (>>) |
| SALL1 → FOS (>>) |
| SALL1 → MLXIPL (>>) |
| SALL1 → BCL6 (>>) |
| SALL1 → PEG3 (>>) |
| SALL1 → MEIS2 (>>) |
| SALL1 → NFAT5 (>>) |
| SALL1 → ONECUT2 (>>) |
| SALL1 → CEBPA (>>) |
| SALL1 → SNAPC4 (>>) |
| SALL1 → MSL3 (>>) |
| SALL1 → RB1 (>>) |
| SALL1 → CITED2 (>>) |
| SALL1 → RXRA (>>) |
